The company's lead candidate VMT-a-NET is in Phase 1/2a clinical trials for neuroendocrine tumors, while VMT01 targets melanoma, PSV359 targets fibroblast activation protein alpha, and PSV4XX targets prostate-specific membrane antigen. Perspective has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate VMT01 in combination with nivolumab in melanoma patients.
Cyborg Score Rationale
According to 10 analysts, the average rating for CATX stock is "Strong Buy" with a 12-month stock price target of $12.2, representing a 126.77% upside from the latest price. The company has a promising TAT pipeline and recent capital raise, though it remains pre-commercial with significant losses.
Top Insights
Lead candidate VMT-a-NET achieved 76% progression-free survival in neuroendocrine tumors, positioning it favorably versus competitors
Recently raised $175 million (Feb 2026) to advance pipeline, with analyst price targets ranging from $6 to $21
Competitive advantage through proprietary 212Pb technology enabling targeted delivery with reduced systemic toxicity
Bristol Myers Squibb partnership validates approach but creates some dependence on larger pharma collaboration
Named Competitors
Lutathera — Beta-emitting somatostatin receptor targeted radiopharmaceutical for neuroendocrine tumors
Pluvicto — PSMA-targeted beta emitter for castration-resistant prostate cancer